Compare Charles River Laboratories Intl. Inc (CRL) vs Crocs, Inc. (CROX) Price & Performance

CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.

The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.

Crocs (CROX) trades at $117.64, up 2.12% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but maintains strong fundamentals including a 10.37 P/E ratio and 42.3% ROE. Recent management commentary highlights product innovation and HEYDUDE brand repositioning as growth catalysts. Cash flow trends show consistent operational strength despite recent net income volatility.

The outlook remains cautiously optimistic with analyst consensus targeting $136.78 (16% upside). Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification. The combination of attractive valuation, strong profitability metrics, and positive earnings surprises supports potential long-term appreciation despite near-term technical weakness.